Randomized triple-blind trial reveals synbiotics improve lipid profiles in chronic heart failure patients, suggesting potential cardiovascular metabolic benefits.
Background: Cardiovascular disease is one of the leading causes of death worldwide. Evidence suggests that alterations in the gut microbiome could play a role in cardiovascular diseases including heart failure. Objective : The purpose of this study was to evaluate the effect of synbiotics on serum paraoxonase 1(PON1), (sCD163/sTWEAK) and lipid profile, which are involved in heart failure in patients with chronic heart failure. Method : In this triple-blind randomized clinical trial, 90 eligible patients were included in the study. They were randomly assigned to receive one capsule (500 mg) of synbiotics or a placebo per day for 10 weeks. serum paraoxonase 1(PON1), (sCD163/sTWEAK), and lipid profile were measured at the beginning and end of the study. The data were analyzed by SPSS 24, and the p-value <0.05 was considered statistically significant. Result: Among 90 patients who met the inclusion criteria, 80 patients completed the study. At the end of the intervention, and after adjusting for the effect of confounders, the levels of total cholesterol (TC), LDL-c, Triglyceride and TC/HDL-C showed a significant decrease. However, we found no significant differences between the groups when considering other study indices. Conclusion: A favorable effect of synbiotics on the lipid profile of patients with heart failure was observed, but no statistically significant effect was found on paraoxinase1, sCD163, and sTWEAK factors Registration number: IRCT20091114002709N55
No takes yet. Share an insight, caveat, or question.
Matin et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: